Table 2.
The proportions of TMIT based on PD‐L1 expression and CD8+ tumor‐infiltrating lymphocytes between lung adenocarcinoma and squamous cell carcinoma
| TMIT | LAC n (%) | SCC n (%) | P |
|---|---|---|---|
| Tumor cell PD‐L1 and TILs tumor islets | <.0001 | ||
| TMIT I (PD‐L1high and TILhigh) | 25 (12) | 52 (35) | |
| TMIT II (PD‐L1low and TILlow) | 69 (34) | 33 (22) | |
| TMIT III (PD‐L1high and TILlow) | 65 (32) | 47 (32) | |
| TMIT IV (PD‐L1low and TILhigh) | 46 (22) | 17 (11) | |
| Tumor cell PD‐L1 and TILs tumor stromal | .0002 | ||
| TMIT I (PD‐L1high and TILhigh) | 56 (27) | 69 (46) | |
| TMIT II (PD‐L1low and TILlow) | 55 (27) | 21 (14) | |
| TMIT III (PD‐L1high and TILlow) | 34 (17) | 30 (20) | |
| TMIT IV (PD‐L1low and TILhigh) | 60 (29) | 29 (20) |
Abbreviations: LAC, lung adenocarcinoma; PD‐L1, programmed cell death ligand 1; SCC, squamous cell carcinoma; TIL, tumor‐infiltrating lymphocytes; TMIT, tumor microenvironment immune types.